secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001104659-24-012280
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Q1 revenue down 83% to $891K; operating loss widens to $3.8M
------------------------------------------------------------------------

- Revenue $891K vs $5.3M YoY, down 83% due to COVID-19 testing decline (CUNY contract ended) and lower cotton DNA tagging revenue.
- Operating loss $3.8M vs $1.2M YoY; Adjusted EBITDA negative $3.2M vs negative $1.1M.
- Cash $3.4M at Dec 31 vs $7.2M at Sep 30; post-quarter closed $3.44M direct offering with warrants.
- Company projects initial GMP facility capacity enabling up to $15M annual Linea IVT revenue, expected online H1 2024.
- Clinical-stage mRNA customer evaluation: Linea IVT templates met/exceeded all metrics, fastest manufacturing speed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465924012280/0001104659-24-012280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465924012280/tm245568d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-012280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer